Alpha Teknova, Inc. · NASDAQ:TKNO
Alpha Teknova — Q4 2025 Earnings Presentation
21 slides from Alpha Teknova's earnings presentation, Feb 26, 2026
Slide 1: Financial Results: Q4:2025 and Full Year 2025
FINANCIAL RESULTS: Q4:2025 and Full Year 2025 SLIDE SUPPLEMENT NASDAQ: TKNO February 26, 2026
Slide 2: Forward-looking statements and use of non-GAAP financial measures
Forward-looking statements and use of non-GAAP financial measures This meeting is for the purpose of familiarizing you with Alpha Teknova, Inc. ("Teknova") and is made for informational purposes only and nothing in the presentation should be viewed, or construed, as “advice”. You understand and agre
Slide 3: Agenda
Agenda • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2026 Outlook Matt Lowell, Chief Financial Officer • Q&A © 2026 Alpha Teknova, Inc. ● Financial Results | Q4:2025 and Full Year 2025 ● Slide Supplement 3
Slide 4: We Make Solutions Possible
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics TOTAL 2025 REVENUE Y/Y REVENUE GROWTH PROJECT ADJ. EBITDA + $40.5M 7% 2027 ACTIVE CUSTOMERS CLINICAL CUSTOMER # THERAPIES 3,000+ % GROWTH SUPPORTE
Slide 5: Our products are fundamental to the life sciences industry
Our products are fundamental to the life sciences industry LIQUID MICROBIAL MOLECULAR AGAR PLATES CULTURE MEDIA BIOLOGY REAGENTS AND SUPPLEMENTS Extensive selection of standard Wide variety of liquid media Offering a vast range of product and specialty pre-poured agar and broths to expand a particul
Slide 6: Primary End Market Segments
2025 REVENUE BREAKDOWN Primary End Market Segments REVENUE BY END MARKET SEGMENT FY:2025 5% Non- Product APPROX. APPROX. APPROX. 1,000 400 1,900* Revenue * * ACCOUNTS ACCOUNTS ACCOUNTS BIOPHARMA AND ~15% LIFE SCIENCE TOOLS OTHER MARKET Other Market CONTRACT AND DIAGNOSTICS SEGMENTS Segments MANUFACT
Slide 7: Revenue by Product Type and Customer End Market
Revenue by Product Type and Customer End Market OTHER Total 2024 Revenue by Product~5% Type and End Market 2025 REVENUE BREAKDOWN CLINICAL • Lab Essentials: ~75% of 2025 Revenue SOLUTIONS § Catalog product revenue comprises ~75% ~20% 15% CLINICAL § Custom product revenue comprises ~25% Catalog SOLUT
Slide 8: Why we win
Why we win CATALOG BUSINESS FASTER AS A FOUNDATION SMALLER CUSTOM TURNAROUND TIME BATCH SIZES Relative Annual Spend Initial Build Sizes for Custom Time from Order to Shipment by Account Type in 2025 Research and Clinical Orders for Custom Orders 44X 10,000 L MONTHS QC 1,000 L Typical batch size for
Slide 9: Q4:25 and Full Year 2025 Financials
Q4:25 and Full Year 2025 Financials
Slide 10: Q4:2025 Revenue Highlights
Q4:2025 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $10.0 • Total fourth quarter revenue up 8% $9.3 compared to the same period in prior 8% y/y year $2.7 $1.9 • Lab Essentials was flat compared to the same period in prior year • Clinical Solutions increased 47% from the same period in
Slide 11: FY:2025 Revenue Highlights
FY:2025 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $40.5 $37.7 • Total annual revenue up 7% compared 7% y/y to the same period in prior year $7.7 $7.1 • Lab Essentials increased 7% from prior year • Clinical Solutions increased 8% from prior year $28.9 $31.0 FY:2024 FY:2025 Lab Essen
Slide 12: Historical Customer Metrics by Product Category
Historical Customer Metrics by Product Category NON-GAAP FIGURES: LAB ESSENTIALS CLINICAL SOLUTIONS Number of 3,374 3,255 3,045 60 Customers1 2,754 2,826 48 2,008 34 21 24 13 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Average Revenue $10,578 $10,191 $369 $352 $9,871 $9,761 $9,486 $9
Slide 13: Q4:2025 Income Statement Highlights
Q4:2025 Income Statement Highlights Gross Margin (%) Total OpEx ($M) 32.5% $7.8 $7.9 23.0% OpEx is $7.4M excluding non-recurring transaction costs ($0.5M) Q4:2024 Q4:2025 Q4:2024 Q4:2025 Adjusted EBITDA1 ($M) Diluted EPS ($) ($1.8) ($0.09) ($3.2) ($0.11) Q4:2024 Q4:2025 Q4:2024 Q4:2025 1 Adjusted EB
Slide 14: FY:2025 Income Statement Highlights
FY:2025 Income Statement Highlights Gross Margin (%) Total OpEx ($M) Gross Margin was 33.2% $33.4 OpEx is $32.0M 26.5% excluding non- excluding severance OpEx is $29.9M 19.2% recurring, non-cash charges related to the pay and other termination benefits $30.4 excluding non- recurring transaction expi
Slide 15: Q4:2025 Cash Flow and Balance Sheet Highlights
Q4:2025 Cash Flow and Balance Sheet Highlights Capital Expenditure ($M) Free Cash Flow1 ($M) ($0.8) ($1.5) $0.6 $0.3 Q4:2024 Q4:2025 Q4:2024 Q4:2025 Cash, Cash Equivalents, and Short-Term Investment was $21.3M as of December 31, 2025 1 Free Cash Flow equals cash provided by (used in) operating activ
Slide 16: FY:2025 Cash Flow and Balance Sheet Highlights
FY:2025 Cash Flow and Balance Sheet Highlights Capital Expenditure ($M) Free Cash Flow1 ($M) ($9.8) ($13.5) $1.1 $1.1 FY:2024 FY:2025 FY:2024 FY:2025 Cash, Cash Equivalents, and Short-Term Investment was $21.3M as of December 31, 2025 1 Free Cash Flow equals cash provided by (used in) operating acti
Slide 17: Quarterly Financial Trends
Quarterly Financial Trends Gross Margin1 (%) Total OpEx ($M) $12.1 $12.2 $11.4 $10.2 $10.2 $7.9 $7.8 $8.0 $7.9 $7.5 $7.4 $7.2 44% 39% 32% $10.7 $9.9 $9.8 29% 30% 31% 31% $9.7 $8.9 27% 24% $7.8 $7.5 $7.8 $8.0 $7.4 $7.4 23% $7.2 18% 17% Q1:23 Q2:23 Q3:23 Q4:23 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25
Slide 18: 2026 Outlook and Capital Runway
2026 Outlook and Capital Runway GUIDANCE • Estimate total revenue between $42–44 million, up 6% y/y at the midpoint • We are targeting free cash outflow of less than $10 million for 2026 CAPITAL RUNWAY ASSUMPTIONS • Estimate annualized revenue range of $52-57 million to achieve Adjusted EBITDA break
Slide 19: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 20: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2026 Alpha Teknova, Inc. ● Financial Results | Q4:2025 and Full Year 2025 ● Slide Supplement 20
Slide 21: teknova
teknova: